China Pharma Holding (China Pharma Holding) Debt-to-Equity : 0.62 (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is China Pharma Holding Debt-to-Equity?

China Pharma Holding's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.18 Mil. China Pharma Holding's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.45 Mil. China Pharma Holding's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $7.46 Mil. China Pharma Holding's debt to equity for the quarter that ended in Dec. 2023 was 0.62.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for China Pharma Holding's Debt-to-Equity or its related term are showing as below:

CPHI' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.19 Med: 0.44 Max: 2.08
Current: 0.62

During the past 13 years, the highest Debt-to-Equity Ratio of China Pharma Holding was 2.08. The lowest was 0.19. And the median was 0.44.

CPHI's Debt-to-Equity is ranked worse than
72.68% of 853 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs CPHI: 0.62

China Pharma Holding Debt-to-Equity Historical Data

The historical data trend for China Pharma Holding's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Pharma Holding Debt-to-Equity Chart

China Pharma Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.72

0.93

2.08

2.04

0.62

China Pharma Holding Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															2.04	1.85	1.79	0.88	0.62

Competitive Comparison of China Pharma Holding's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Pharma Holding's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where China Pharma Holding's Debt-to-Equity falls into.

China Pharma Holding Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

China Pharma Holding's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.182	+	1.452)	/	7.455
	=	0.62

China Pharma Holding's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.182	+	1.452)	/	7.455
	=	0.62

China Pharma Holding (OTCPK:CPHI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

China Pharma Holding Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of China Pharma Holding's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

China Pharma Holding (China Pharma Holding) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Pharma Holding Inc (OTCPK:CPHI) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Second Floor, No. 17, Jinpan Road, Hainan Province, Haikou, CHN, 570216

Website

https://www.chinapharmaholdings.com

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.

Executives

Ke Deng	10 percent owner	NO.17, JINPAN ROAD, SECOND FLOOR, HAIKOU F4 570216
Frank Waung	officer: Chief Financial Officer	72 GREAT HILLS RD., SHORT HILLS NJ 07078
G Michael Bennett	director	4/F, NO. 3 JINYUAN ROAD, DAXING DISTRICT INDUSTRIAL DEVELOPMENT A, BEIJING F4 102600
Yingwen Zhang	director	NO. 5, UNIT 1, BLDG. 4, NO. 14 XIN NAN ZHI RD., CHENGDU, SICHUAN F4 610041
Baowen Dong	director	NO.9, BLDG. 9, SOUTH PARK, NO. 24, SECTION 1, 1ST RING ROAD, CHENGDU, SICHUAN F4 610041
Heung Mei Tsui	director, 10 percent owner	FLAT F, 3RD FL., MAYSON GARDEN BLDG., 68 HING FAT ST., CAUSEWAY BAY, HONG KONG F4 XXXXX
Zhilin Li	officer: President and CEO	2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVINCE F4 570216
Jian Yang	officer: Secretary	NO. 1 HAOYUAN ROAD, XINHUA DISTRICT, HAIKOU, HAINAN PROVI F4 570216
Xinhua Wu	officer: CFO	2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVI F4 570216
George L Diamond	10 percent owner	174 FM 1830, ARGYLE TX 76226
David F Brigante	10 percent owner	174FM 1830, ARGYLE TX 76226
Marat Rosenberg	10 percent owner	17 FM 1830, ARGYLE TX 76226
Halter Financial Investments Lp	10 percent owner	174 FM 1830, ARGYLE TX 76226
Halter Financial Investments Gp Llc	10 percent owner	174 FM 1830, ARGYLE TX 76226
Timothy P Halter	director, 10 percent owner, officer: CEO, President & CFO	174 FM 1830, ARGYLE TX 76226